Research & Development
Policy & Regulation
Trends & Finance
Meridian Bioscience Q4 revenues drop 14% on lower COVID-19 testing, misses analysts' estimates
Diagnostics segment revenue growth was driven by nonmolecular assay products, which increased 22%.
November 22, 2022
Agilent Technologies Q4 revenues rise 11%
The Diagnostics and Genomics Group generated fourth-quarter revenue of $352 million, up 3% year-over-year.
November 21, 2022
Twist Bioscience Q4 revenues rise 51%
Among its recent business highlights, the firm noted that it collaborated with PacBio to develop an initial portfolio of off-the-shelf long-read gene panels, including a 50-gene pharmacogenomics panel.
November 18, 2022
Siemens Healthineers Q4 Dx revenues rise 13% on increased sales of COVID-19 rapid antigen tests
In the recently completed quarter, Siemens Healthineers booked €232 million from COVID-19 rapid antigen tests compared to around €160 million in Q4 2021.
November 9, 2022
Qiagen Q3 net sales decline 7% on COVID challenges, but full-year outlook improves
Sales of non-COVID-19 products increased 11% year over year to $417 million, while sales of COVID-19 products fell 48% year over year to $83 million.
November 8, 2022
PerkinElmer Q3 revenues down 14% on diagnostics decline
Discover and Analytical Solutions segment revenues of $312.8 million were up 51% compared year-over-year but, Q3 Diagnostics segment revenues of $399 million declined 39% year-over-year.
November 8, 2022
Chembio Diagnostics applies for FDA CLIA waiver for HIV, syphilis test
Dr. Fauci invokes Yogi Berra to describe emerging infectious disease challenge
Thermo Fisher Scientific introduces digital PCR liquid-biopsy assays for academic, clinical research
Thermo Fisher Scientific updates Applied Biosystems genetic analyzers to comply with IVDR
Week in Review: Elizabeth Holmes sentenced; good cholesterol worse for some adults; earlier type 2 diabetes diagnosis; and more
Quest Diagnostics completes acquisition of Summa Health outreach lab services business
Illumina reports 1% rise in third-quarter revenues
Third-quarter revenue was $1.12 billion. For full-year 2022, the company expects consolidated revenue to be flat to 1% higher than fiscal year 2021.
November 7, 2022
Exact Sciences shares rise with 15% growth in Q3 revenues
Screening segment revenue, including sales for the Cologuard colon cancer molecular test, was $360.8 million, an increase of 29% year-over-year.
November 4, 2022
QuidelOrtho reports 54% rise in Q3 revenues, identifies additional cost synergies from business combination
The firm added that for the quarter ended October 2, its total supplemental combined revenue of $783.8 million decreased by 24%.
November 3, 2022
Renalytix fiscal 2022 revenues double on sales for kidney health risk testing
Among the highlights for the year, the company obtained reimbursement status for its KidneyIntelX test based on Medicare clinical lab fee schedule pricing of $950 per test.
October 31, 2022
Hologic fiscal Q4 revenue drops 28% on COVID testing, supply chain challenges
Excluding COVID-19, Diagnostics revenue grew 11% on an organic, constant currency basis.
October 31, 2022
DiaSorin revenues rise 18% for 1st 9 months despite COVID sales decline
Growth was driven in part by including Luminex, which contributed 277 million euros overall during the first nine months of 2022.
October 28, 2022
Page 1 of 8